drugset / Trial / NCT03769506
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Timeline
- Start
- 2019-05-09
- Primary completion
- 2025-12
- Completion
- 2025-12
Publications
- Background Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021 Jan 1;33(1):7-15. doi: 10.1093/intimm/dxaa037.
- Background Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23.
- Magagoum SH, Biteghe FAN, Siwe GT, Lang D, Lekena N, Barth S. SNAP-Tag-Based Recombinant Photoimmunotherapeutic Agents for the Selective Detection and Killing of Light-Accessible Melanotransferrin-Expressing Melanoma and Triple-Negative Breast Cancer. Cancer Med. 2025 May;14(9):e70912. doi: 10.1002/cam4.70912.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CETUXIMAB SAROTALOCAN | Other / unclassified | — | — |
| Comparator | Cetuximab | Monoclonal antibody | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Methotrexate | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |